Abstract
The bee venom is used for treating a wide variety of conditions from acute tendonitis to chronic back pain to rheumatoid arthritis (RA). The major treatment is gene therapy or recombinant DNA vaccines involved in targeting multiple antigenic components to direct and empower the immune system to protect the host from infection. Limitations of therapy for the treatment of patients suffering from various adverse reaction and contraindications are always experienced. Antigenic epitopes on melittin protein of Apis dorsata are important determinants of protection against rheumatoid arthritis. As our knowledge of the immune responses to a protein antigen progressed, it became clear that the whole protein is not necessary for raising the immune response, but small segments as 4-AILKVLSTGLPALIS-18 of protein called the antigenic determinants or the epitopes, are sufficient for eliciting the desired immune response. Immunization cassettes should be capable of immunizing broad immunity against both humoral and cellular epitopes, thus giving vaccines the maximum ability to deal with A. dorsata immune escape against rheumatoid arthritis.
Keywords: Antigenic epitope, secondary structure, hydrophobicity, hydrophilicity
Current Proteomics
Title: Antigenicity Prediction in Melittin: Possibilities of in Drug Development from Apis dorsata
Volume: 4 Issue: 2
Author(s): V. S. Gomase and S. S. Changbhale
Affiliation:
Keywords: Antigenic epitope, secondary structure, hydrophobicity, hydrophilicity
Abstract: The bee venom is used for treating a wide variety of conditions from acute tendonitis to chronic back pain to rheumatoid arthritis (RA). The major treatment is gene therapy or recombinant DNA vaccines involved in targeting multiple antigenic components to direct and empower the immune system to protect the host from infection. Limitations of therapy for the treatment of patients suffering from various adverse reaction and contraindications are always experienced. Antigenic epitopes on melittin protein of Apis dorsata are important determinants of protection against rheumatoid arthritis. As our knowledge of the immune responses to a protein antigen progressed, it became clear that the whole protein is not necessary for raising the immune response, but small segments as 4-AILKVLSTGLPALIS-18 of protein called the antigenic determinants or the epitopes, are sufficient for eliciting the desired immune response. Immunization cassettes should be capable of immunizing broad immunity against both humoral and cellular epitopes, thus giving vaccines the maximum ability to deal with A. dorsata immune escape against rheumatoid arthritis.
Export Options
About this article
Cite this article as:
Gomase S. V. and Changbhale S. S., Antigenicity Prediction in Melittin: Possibilities of in Drug Development from Apis dorsata, Current Proteomics 2007; 4 (2) . https://dx.doi.org/10.2174/157016407782194639
DOI https://dx.doi.org/10.2174/157016407782194639 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Thermal and Shear Stressors on the Physical Properties, Structural Integrity and Biological Activity of the Anti-TNF-alpha Monoclonal Antibody, Infliximab
Current Pharmaceutical Biotechnology Pleuroparenchymal Fibroelastosis: Associations and Underlying Conditions
Current Respiratory Medicine Reviews Evaluating the Relationship Between Serum Level of Interleukin-6 and Rheumatoid Arthritis Severity and Disease Activity
Current Rheumatology Reviews The Usefulness of Phalangeal Quantitative Ultrasound in the Assessment of Skeletal Status in Children and Adolescents
Current Medical Imaging Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF) and its Possible Role in Tumour Progression During Malignant Transformation of Atrophic Epithelium in Oral Submucous Fibrosis
Current Angiogenesis (Discontinued) Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry Road Towards New Antimalarials – Overview of the Strategies and their Chemical Progress
Current Medicinal Chemistry Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis
Current Pharmaceutical Design What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews The Use of Cyclosporine in Respiratory Diseases
Current Respiratory Medicine Reviews Ionic Liquid as a Green Media for the One-Pot Synthesis of New α- Thiazolodepsipeptide Derivatives via a Four-Component Reaction
Letters in Organic Chemistry Production of 68Ga-citrate Based on a SnO2 Generator for Short-Term Turpentine Oil-Induced Inflammation Imaging in Rats
Current Radiopharmaceuticals Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Synovial Fluid and Serum Concentrations of Inflammatory Markers in Rheumatoid Arthritis, Psoriatic Arthritis and Osteoarthitis: A Systematic Review
Current Rheumatology Reviews Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued)